BeOne Medicines (ONC) Gets FDA Priority Review For First Line Lymphoma Regimen

Simply Wall St.11-06

BeOne Medicines (NasdaqGS:ONC) received U.S. FDA Priority Review for BRUKINSA plus rituximab in first-line mantle cell lymphoma. The chemotherapy free regimen is based on a pivotal Phase 3 trial that ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment